PERCEPTIVE INFORMATICS ENHANCES ITS eCLINICAL PLATFORM WITH IBM TECHNOLOGIES
BOSTON, MA, October 18 , 2010 — Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced that it is bringing further advancements to its eClinical platform. Perceptive has incorporated IBM’s WebSphere® portal and Tivoli® Access Manager into its eClinical platform, which provides support for its eClinical Suite.
Powered by foundational technologies that enable applications within its eClinical Suite, Perceptive’s eClinical platform incorporates reporting, integration, and identity management solutions, among others. The platform technologies from IBM allow Perceptive to support more extensive interoperability between its systems and facilitate a single entry point for users. The technologies also provide support for Perceptive’s eClinical solutions offered as Software-as-a-Service (SaaS) applications, which are developed to be hosted by Perceptive.
“As the number of technologies used in clinical trials increases, Perceptive is committed to expanding our robust and flexible enterprise platform to meet customer demand for innovative, sophisticated, and easily accessible eClinical solutions,” said Nicholas Richards, Vice President, Product Development, Perceptive Informatics. “The solutions Perceptive is developing are fundamentally changing the way technology is accessed and used in clinical trials. Our customers can benefit from foundational technologies that further enhance the capabilities of our eClinical Suite to bring more efficiency to biopharmaceutical development.”
IBM’s WebSphere portal framework enhances the Perceptive Portal enterprise solution, which provides secure, centralized access to clinical trial documentation and training materials as well as a collaboration area to develop related materials. The portal’s reporting engine displays consolidated trial metrics, allowing study performance to be easily tracked using data drawn from multiple sources. Perceptive has incorporated IBM’s Tivoli Access Manager to improve single sign-on functionality. Designed to streamline workflow, this advancement eliminates the need for multiple user names and passwords by providing access to various systems with one set of credentials.
The eClinical Suite from Perceptive Informatics provides advanced integration and interoperability among systems, including the IMPACT® Clinical Trial Management System (CTMS), the DataLabs® EDC solution, and the ClinPhone® Randomization and Trial Supply Management (RTSM) technologies. The suite supports real-time data interchange and enables diverse applications to work synergistically. For more information about Perceptive’s eClinical Suite visit: http://www.perceptive.com/Solutions/eClinical-Suite.html.
IBM, the IBM logo, ibm.com, Tivoli and WebSphere are trademarks of International Business Machines Corporation, registered in many jurisdictions worldwide. A current list of other IBM trademarks is available on the Web at “Copyright and trademark information” at http://www.ibm.com/legal/copytrade.shtml.
About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive’s eClinical Suite visit: www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 54 countries around the world, and has approximately 9,720 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended June 30, 2010 as filed with the SEC on August 27, 2010, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.